Our pipeline
We are passionate about science.
We have a diversified and balanced clinical development pipeline that covers multiple therapeutic areas, including CNS, cardiovascular and immunological disorders, as well as orphan diseases.
|
Compound |
Mechanism of Action |
Target Indication |
Status |
More Information |
|
Daridorexant |
Dual orexin receptor antagonist |
Insomnia |
Commercially available as QUVIVIQ™ in the US Approved in the EU Under review in Switzerland and Canada Phase 3 in Japan – recruitment complete Phase 2 in pediatric insomnia – recruiting |
|
|
Aprocitentan* |
Dual endothelin receptor antagonist |
Resistant hypertension management |
Phase 3 successful – filing by end 2022 |
|
|
Clazosentan |
Endothelin receptor antagonist |
Cerebral vasospasm assoc. |
Commercially available as PIVLAZ™ in Japan Global Phase 3 – recruitment complete |
|
|
Lucerastat |
Glucosylceramide synthase inhibitor |
Fabry disease |
Phase 3 primary endpoint not met, Open Label Extension study (OLE) ongoing |
|
|
Selatogrel |
P2Y12 receptor antagonist |
Suspected acute myocardial infarction |
Phase 3 recruiting |
|
|
Cenerimod |
S1P1 receptor modulator |
Systemic lupus erythematosus |
Phase 3 in preparation |
|
|
ACT-539313 |
Selective orexin 1 receptor antagonist |
Under evaluation |
- |
|
|
ACT-1004-1239 |
ACKR3 / CXCR7 antagonist |
Multiple Sclerosis |
Phase 2 in preparation |
|
|
Sinbaglustat |
GBA2/GCS inhibitor |
Rare lysosomal storage disorders |
Phase 1 complete |
|
|
ACT-1014-6470 |
- |
Immunology |
Phase 1 |
|
|
ACT-777991 |
- |
Immunology |
Phase 1 |
* In collaboration with Janssen Biotech to jointly develop aprocitentan, Janssen Biotech has sole commercialization rights worldwide
Neurocrine Biosciences has a global license to develop and commercialize ACT-709478 (NBI-827104), Idorsia's novel T-type calcium channel blocker. ACT-709478 is currently investigated in a Phase 2 study for the treatment of a rare form of pediatric epilepsy.
Innovation fact sheet
For investors, we provide more information on how Idorsia is innovating to change treatment paradigms in our innovation fact sheet. Please visit the investor section for more information.